In glioma, mutations and epigenetic changes such as isocitrate dehydrogenase (IDH) mutations, chromosome 1p/19q co-deletion, and O6-methylguanine–DNA methyltransferase (MGMT) hypermethylation have demonstrated clinical importance. Here, IDH1 is linked to central nervous system cancer.